New York, Feb 28, 2026, 15:25 EST — The final bell has sounded; market closed.
- Synopsys ended Friday with a 2.82% decline at $414, stretching its two-day slide to roughly 8%.
- The company’s quarterly outlook triggered the pullback, as renewed talk swirled about China export restrictions and the pace of core EDA growth.
- Coming up: Synopsys’ Converge conference set for March 11-12, plus its quarterly Form 10-Q, which is due by March 12.
Synopsys shares slipped 2.8% to $414 on Friday, logging a second consecutive decline as trading volume punched above typical levels. The stock has dropped roughly 8% since Wednesday’s close. U.S. markets resume trading Monday.
This shift is grabbing chip investors’ attention. Synopsys supplies electronic design automation, or EDA, software — the key toolkit engineers turn to for chip design and testing ahead of production. If EDA budgets tighten, it may signal a wider pullback in chip R&D spending.
Synopsys shares came under pressure after the company’s quarterly report highlighted renewed concerns around China exposure and its Design IP segment. The company is projecting second-quarter revenue between $2.23 billion and $2.28 billion, with adjusted earnings of $3.11 to $3.17 per share. Synopsys noted that ongoing export restrictions in China have delayed new chip design work for some clients. Revenue in its Design IP division, which supplies ready-made circuit designs, dropped over 6% to $407 million. “Excluding Ansys, China revenue declined slightly year‑over‑year, consistent with our outlook,” CFO Shelagh Glaser told analysts on the call. Reuters
Synopsys posted quarterly revenue of $2.409 billion, with non-GAAP earnings per share at $3.77—excluding certain items not tied to its core business. The company stuck with its full-year revenue guidance of $9.56 billion to $9.66 billion, noting that the forecast relies on current export control restrictions staying put. The board cleared an additional $2.0 billion for share buybacks. Synopsys plans to submit its quarterly Form 10-Q to the SEC by March 12. “An expanded portfolio” and “the most compelling roadmap in our history,” is how CEO Sassine Ghazi described Synopsys heading into 2026. Synopsys Investor Relations
Morgan Stanley dialed back its outlook on Synopsys early Friday, moving the stock to Equalweight from Overweight and slashing the target price down to $480, from $550. The firm flagged that Synopsys’ core EDA business—excluding Ansys—is now running at just high single-digit growth year-on-year. Competition could ramp up in 3D-IC, the multi-die chip packaging space, and in emulation focused on “physical AI” use cases, Morgan Stanley cautioned. The AgentEngineer unit, they added, remains in its early stages, and the timeline for any meaningful scale-up is murky. Investing.com
One day earlier, Needham took a more upbeat stance, keeping its Buy rating and $580 price target in place after the quarter. The firm described fiscal 2026 as a transition year. It highlighted Synopsys’ focus on “value selling”—specifically, IP monetization with hyperscalers and upselling into the Ansys customer base. China remains a headwind, Needham noted. Investing.com
Mark March 11-12 for Synopsys’ Converge event at the Santa Clara Convention Center. Ghazi is on tap to kick things off with a keynote at 9:00 a.m. PT that first day. The program pulls together Synopsys’ user conference, a simulation track, and an executive forum under one roof.
Traders are now debating if Synopsys’ slide after earnings amounts to little more than unwinding positions following a turbulent stretch, or if it signals a deeper shift in the market’s view of the company’s growth story. Expect attention to zero in on China bookings, developments in the Design IP pipeline, and the pace at which the Synopsys-Ansys collaboration could begin to make a financial impact.
Still, the risks are clear. If U.S. export rules get stricter or if major chipmakers start cutting back on spending, demand for China and IP could take a hit. Competition among EDA vendors doesn’t help—pricing and share in key design segments can get squeezed fast. With the stock trading at a lofty price-to-earnings multiple, even small signals of slowing core growth could rattle investors.
U.S. markets reopen Monday, March 2. The next key event lands March 11 with Converge, and investors want sharper updates on profitable growth, initial joint offerings, and any shifts in Synopsys’ run rate after the Ansys integration.
